The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Now that 2018 is nearing an end, it is a serious time for investors to start thinking about expectations in 2019 rather than looking back at how choppy 2018 has been.
24/7 Wall St. screened the Merrill Lynch research database for stocks rated Buy that pay a dividend and have the firm's best volatility risk rating. These five that look like solid picks…
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
The demand for drugs to treat erectile dysfunction has risen to meet the needs of an aging population and to help combat disease-related causes.
Caterpillar, UnitedHealth, Microsoft, and Pfizer lifted the down to 500-point gain Wednesday.
Nektar shares dipped on Tuesday after the company announced that it would be collaborating with Pfizer to evaluate several combination regimens in multiple cancer settings.
Apple, Intel, Pfizer, and Merck were the worst performing Dow stocks on Friday.
The top analyst upgrades, downgrades and initiations seen on Thursday included American Eagle Outfitters, Facebook, Nutrisystem, Pfizer, Roku, SeaWorld, Valero Energy and Zynga.
Pfizer reported mixed quarterly results before the markets opened on Tuesday and shares retreated in the premarket.
Chris Lange Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of the Dow companies scheduled to report their quarterly results this week. Here, we have included the consensus earnings estimates from Thomson Reuters, as…
The October 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These four top pharmaceutical companies have longstanding franchises with huge sales and revenues, and their dividend-paying stocks look like outstanding choices for worried investors to consider now.
Pfizer, in collaboration with Bain Capital, announced the creation of Cerevel Therapeutics, a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system.
Chris Lange 
